Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease

Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology
Arun V KrishnanM C Kiernan

Abstract

To investigate the mechanisms underlying peripheral neuropathy and to provide insights into axonal Na(+)/K(+) pump function in patients with end-stage kidney disease (ESKD). Nerve excitability was assessed in 10 ESKD patients before and after a single session of haemodialysis and in 29 age-matched control subjects. Changes in excitability were recorded at baseline and following maximal voluntary contraction (MVC) of abductor pollicis brevis (APB) for 60s. Serum concentrations of putative neurotoxins including potassium, urea, parathyroid hormone and beta-2-microglobulin were also measured. Baseline excitability values were consistent with axonal depolarisation prior to dialysis. Following maximal voluntary contraction (MVC), there was an increase in threshold, which was associated with reduced strength-duration time constant and increased superexcitability, consistent with axonal hyperpolarisation. These changes were quantitatively similar for patients and controls, arguing against any significant reduction in the axonal Na(+)/K(+) pump in ESKD. Following dialysis, activity-dependent changes were less in ESKD, which suggests greater Na(+)/K(+) pump activity prior to dialysis, the opposite of the changes expected with reduced Na...Continue Reading

Citations

Feb 6, 2010·Critical Care Medicine·Nicola LatronicoBruno Guarneri
Apr 24, 2009·Seminars in Dialysis·Arun V KrishnanMatthew C Kiernan
Jun 4, 2014·PloS One·Delphine BoërioWerner J Z'Graggen
Sep 6, 2011·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Joseph Bergmans
Aug 25, 2009·Progress in Neurobiology·Arun V KrishnanMatthew C Kiernan
Sep 28, 2007·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Konrad MaurerMartin Koltzenburg
Apr 25, 2007·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·S K JankelowitzDavid Burke
Aug 12, 2009·Muscle & Nerve·Arun V KrishnanMatthew C Kiernan
May 21, 2013·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Ria ArnoldArun V Krishnan
Oct 11, 2014·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Arun V Krishnan
Oct 23, 2010·Experimental Neurology·Susanna B ParkMatthew C Kiernan
Oct 17, 2016·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Adeniyi A BorireArun V Krishnan
May 31, 2017·Muscle & Nerve·Adeniyi A BorireArun V Krishnan
Dec 30, 2006·Muscle & Nerve·Arun V Krishnan, Matthew C Kiernan
Mar 19, 2008·Journal of the Peripheral Nervous System : JPNS·Arun V KrishnanMatthew C Kiernan
Sep 3, 2009·Nature Reviews. Neurology·Arun V Krishnan, Matthew C Kiernan
Mar 26, 2008·Brain : a Journal of Neurology·Arun V KrishnanMatthew C Kiernan
May 15, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ranjani N MoorthiElsa S Strotmeyer
Apr 24, 2019·Medicina·Beata Januszko-GiergielewiczAlicja Dębska-Ślizień
Dec 24, 2018·International Journal of Rheumatic Diseases·Nillie EzzeldinMona Amer
Aug 5, 2020·International Journal of Clinical Practice·Shih-Yi LinChia-Hung Kao
Sep 1, 2019·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Matthew C KiernanDavid Burke

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.